Immune cells are present in normal breast tissue and in breast carcinoma. The nature and
distribution of the immune cell subtypes in these tissues are reviewed to promote a better …

Inflammation is now recognized as a hallmark of cancer. Genetic changes in the cancer cell
are accepted as the match that lights the fire, whilst inflammation is seen as the fuel that …

The dynamic interplay between neoplastic cells and the immune microenvironment
regulates every step of the metastatic process. Immune cells contribute to invasion by …

Ductal carcinoma in situ (DCIS) is an often-diagnosed breast disease and a known, non-
obligate, precursor to invasive breast carcinoma. In this review, we explore the clinical and …

Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing
due to widespread use of mammographic screening. It presents several diagnostic and …

Ductal carcinoma in situ (DCIS) is a pre-invasive form of breast cancer where neoplastic
luminal cells are confined to the ductal tree. While as many as 70% of DCIS cases will …

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and
guidelines for their assessment have been published. This study aims to evaluate:(a) …

Tumour‑infiltrating lymphocytes (TILs) are regarded as significant prognostic markers in
patients with breast cancer. However, the prognostic utility of TIL expression based on the …

The drivers of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition
are poorly understood. Here, we conducted an integrated genomic, transcriptomic, and …

Background Ductal carcinoma in situ (DCIS) is treated to prevent subsequent ipsilateral
invasive breast cancer (iIBC). However, many DCIS lesions will never become invasive. To …